Lipocine (LPCN)
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery tech...
- Open
- 2.200
- High
- 2.250
- Low
- 2.120
- Prev. Close
- 2.220
- Volume
- 48.49K
- Turnover
- 105.20K
- Avg Price
- 2.170
- Bid/Ask Ratio
- -85.19%
- Amplitude
- 5.86%
- 52wk High
- 12.370
- Volume Ratio
- 1.80
- Turnover Ratio
- 0.74%
Lipocine Analyst Rating
View moreForecast & Rating
Aug 5, 2026Price forecast
$6.00171.49%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Sep 14 at 10:16 AM
Lipocine initiates BLOOM Phase 3 trial of LPCN 1154 oral brexanolone for postpartum depression
- Tip Ranks · Sep 11 at 10:29 AM
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
- PUBT · Sep 11 at 10:11 AM
Lipocine raises sales agent fee to up to 3% under equity distribution agreement
- PUBT · Sep 10 at 10:14 AM
Lipocine to present at H.C. Wainwright Global Investment Conference
